Price$917.29-7.38 (-0.80%)
01:30 PM07:45 PM
News · 26 weeks174-20%
2025-10-262026-04-19
Mix8190d
- Insider40(49%)
- Other29(36%)
- SEC Filings5(6%)
- Earnings3(4%)
- Analyst3(4%)
- Leadership1(1%)
Latest news
25 items- PRThe Longevity Trade Is No Longer a Buzzword — It's a $120 Billion Market, and the FDA Just Cleared the First Cellular Rejuvenation TrialIssued on behalf of Avaí Bio, Inc. Companies mentioned in this commentary include: Avaí Bio, Inc. (OTCQB:AVAI), Eli Lilly and Company (NYSE:LLY), Novo Nordisk A/S (NYSE:NVO), Viking Therapeutics, Inc. (NASDAQ:VKTX), Longeveron Inc. (NASDAQ:LGVN). Key Takeaways: The global anti-aging market generated more than $85 billion in 2025 and is projected to approach $120 billion by 2030, with private investment in longevity science more than doubling to $8.49 billion across 325 deals last year.The U.S. FDA approved 50 new drugs in 2024 and 46 in 2025 — including what researchers are calling the first drug class of "longevity therapeutics" — while big pharma spent more than $65 billion acquiring bi
- INSIDERSEC Form 4 filed by Sulzberger Gabrielle4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERSEC Form 4 filed by Luciano Juan R4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERSEC Form 4 filed by Fyrwald J Erik4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERSEC Form 4 filed by Alvarez Ralph4 - ELI LILLY & Co (0000059478) (Issuer)
- PRLilly to acquire Kelonia Therapeutics to advance in vivo CAR-T cell therapiesKelonia's lead program, KLN-1010, is a potentially first-in-class lentiviral in vivo CAR-T therapy currently in Phase 1 for relapsed/refractory multiple myeloma with clinical data recently highlighted in the 2025 ASH Annual Meeting plenary sessionAcquisition expands Lilly's genetic medicine capabilities with a novel in vivo gene delivery and integration technology that has potential for broad applicabilityINDIANAPOLIS and BOSTON, Mass., April 20, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Kelonia Therapeutics, Inc. ("Kelonia"), a clinical-stage biotechnology company pioneering in vivo gene delivery, today announced a definitive agreement for Lilly to acquire Kelonia.Kelonia ha
- PRLilly confirms date and conference call for first-quarter 2026 financial results announcementINDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) will announce its first-quarter 2026 financial results on April 30, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance. The conference call will begin at 10 a.m. Eastern time. Investors, media and the general public can access a live webcast of the conference call through a link that will be posted on Lilly's website at https://investor.lilly.com/webcasts-and-presentations. A replay will also be available on the website following the conference call. About LillyLilly is a medicine company turning science into heali
- PRACHIEVE-4, the longest Phase 3 study of Lilly's Foundayo (orforglipron) to date, reaffirmed its cardiovascular and overall safety profile as well as consistent improvements across key measures of cardiometabolic healthIn ACHIEVE-4, Foundayo met the primary objective of non-inferiority vs. insulin glargine with a 16% lower risk of MACE-4 events and a 23% lower risk of MACE-3 eventsIn a pre-planned analysis, the risk of all-cause death was 57% lower for Foundayo vs. insulin glargine, showing the potential for more comprehensive health benefitsWith these data, Lilly plans to submit Foundayo for the treatment of type 2 diabetes to the U.S. Food and Drug Administration by the end of Q2INDIANAPOLIS, April 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ACHIEVE-4 trial evaluating the efficacy and safety of Foundayo (orforglipron), compared to i
- PRLilly's Jaypirca (pirtobrutinib) significantly extended progression-free survival when added to a venetoclax time-limited regimen in patients with previously treated CLL/SLLBRUIN CLL-322 is the first Phase 3 readout in CLL to utilize and outperform a venetoclax-containing control armThis trial predominantly enrolled a patient population previously treated with covalent BTK inhibitors, highly relevant to current practice These results mark the fourth positive Phase 3 study of pirtobrutinib in CLLINDIANAPOLIS, April 13, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from the Phase 3 BRUIN CLL-322 trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton tyrosine kinase (BTK) inhibitor, plus venetoclax and rituximab versus venetoclax and rituximab in patients with relapsed or refractory chronic lymphocyti
- PRFoundayo™ (orforglipron), Lilly's new oral GLP-1 pill for weight loss, now available in the U.S.Foundayo is now available via LillyDirect® and telehealth providers and is shipping to retail pharmacies nationwide Foundayo, the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictions, starts at $25 per month with commercial coverage and $149 per month with self-payINDIANAPOLIS, April 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced that Foundayo™ (orforglipron) is now available to adults with obesity or overweight with weight-related medical problems following the U.S. Food and Drug Administration (FDA) approval on April 1, 2026. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps i
- PRFDA approves Lilly's Foundayo™ (orforglipron), the only GLP-1 pill for weight loss that can be taken any time of day without food or water restrictionsAdults taking Foundayo lost an average of 27 pounds on the highest dose in the ATTAIN-1 clinical trial1Foundayo, Lilly's second FDA-approved obesity medicine, will be available via LillyDirect® with free home delivery, starting at $25 per month with commercial coverage and $149 for self-payINDIANAPOLIS, April 1, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the U.S. Food and Drug Administration (FDA) approved Foundayo™ (orforglipron) for adults with obesity, or overweight with weight-related medical problems. When used alongside a reduced-calorie diet and increased physical activity, Foundayo helps individuals lose excess body weight and keep the weight off. Foundayo
- PRLilly to acquire Centessa Pharmaceuticals to advance treatments for sleep-wake disordersCentessa's OX2R agonist pipeline includes a potential best-in-class therapeutic with significant promise to meaningfully improve outcomes across a range of sleep-wake disordersAcquisition expands Lilly's neuroscience portfolio and capabilities into sleep medicine INDIANAPOLIS and BOSTON and LONDON, March 31, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Centessa Pharmaceuticals plc (NASDAQ:CNTA), a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, today announced a definitive agreement for Lilly to acquire Centessa.Centessa is advancing a pipeline of orexin receptor 2 (OX2R) agonists des
- PRPhase 3b data presented at AAD Annual Meeting show Lilly's Taltz (ixekizumab) plus Zepbound (tirzepatide) delivered superior efficacy for adults with psoriatic arthritis and obesityTaltz and Zepbound used together provided comprehensive improvements in disease activity and patient-reported outcomes compared to Taltz monotherapy in TOGETHER-PsA studyLate-breaking results also published in Arthritis & RheumatologyINDIANAPOLIS, March 28, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced detailed results from the TOGETHER-PsA open-label Phase 3b clinical trial evaluating the concomitant use of Taltz (ixekizumab) and Zepbound (tirzepatide) compared to Taltz alone in adults with active psoriatic arthritis (PsA) and obesity or overweight with at least one additional weight-related comorbid condition. These results were presented in a late-breaking presenta
- PRLilly's EBGLYSS (lebrikizumab-lbkz) delivered up to four years of durable disease control for patients with moderate-to-severe atopic dermatitisIn the ADlong Phase 3b study, nearly all EBGLYSS-treated patients achieved meaningful skin improvement (EASI-75) for up to four years75% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 78% experienced significant itch relief (Pruritus NRS ≤4), one of the most bothersome symptoms for patients80% of patients achieved durable results without the need for topical corticosteroidsINDIANAPOLIS, March 27, 2026 /PRNewswire/ -- New long-term data show Eli Lilly and Company's (NYSE:LLY) EBGLYSS (lebrikizumab-lbkz) delivered durable skin clearance and relief from persistent itch for up to four years for patients with moderate-to-severe atopic dermatitis (eczema) in an open-
- SECSEC Form DEFA14A filed by Eli Lilly and CompanyDEFA14A - ELI LILLY & Co (0000059478) (Filer)
- SECSEC Form DEF 14A filed by Eli Lilly and CompanyDEF 14A - ELI LILLY & Co (0000059478) (Filer)
- PRLilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetesFor the primary endpoint, retatrutide lowered A1C by an average of 1.7% to 2.0% across doses at 40 weeks in TRANSCEND-T2D-1Participants taking retatrutide 12 mg lost an average of 36.6 lbs (16.8%) No weight loss plateau was observed with retatrutide, with participants continuing their weight loss trajectory through 40 weeksINDIANAPOLIS, March 19, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive topline results from TRANSCEND-T2D-1, a Phase 3 clinical trial evaluating the efficacy and safety of retatrutide, an investigational first-in-class GIP, GLP-1 and glucagon triple hormone receptor agonist, as an adjunct to diet and exercise. The trial enrolled adults diagn
- INSIDERDirector Sulzberger Gabrielle was granted 5 shares, increasing direct ownership by 0.17% to 2,976 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Luciano Juan R was granted 16 shares, increasing direct ownership by 0.10% to 16,817 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Fyrwald J Erik was granted 10 shares, increasing direct ownership by 0.01% to 75,259 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- INSIDERDirector Alvarez Ralph was granted 13 shares, increasing direct ownership by 0.02% to 55,601 units (SEC Form 4)4 - ELI LILLY & Co (0000059478) (Issuer)
- ANALYSTEli Lilly downgraded by HSBC Securities with a new price targetHSBC Securities downgraded Eli Lilly from Hold to Reduce and set a new price target of $850.00
- PRLilly's EBGLYSS (lebrikizumab-lbkz) is the first and only selective IL-13 inhibitor to deliver positive Phase 3 outcomes in patients aged six months to 18 years with moderate-to-severe atopic dermatitisIn the Phase 3 ADorable-1 study, 63% of patients achieved meaningful skin improvement (EASI-75) and 44% achieved clear or almost clear skin (IGA 0,1) at Week 16In key secondary endpoints, 39% of patients achieved a high bar of near-complete skin clearance (EASI-90) and 35% achieved significant itch relief (Pruritus NRS ≥4-point improvement)The safety and tolerability profile of EBGLYSS was consistent with adult and adolescent studies, with no injection site pain reportedINDIANAPOLIS, March 16, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced positive, topline results from the Phase 3 ADorable-1 trial evaluating the safety and efficacy of EBGLYSS (lebrikizumab-lbkz) in pe
- SECSEC Form PRE 14A filed by Eli Lilly and CompanyPRE 14A - ELI LILLY & Co (0000059478) (Filer)
- PRLilly Employer Connect platform launches with over fifteen independent program administrators offering tailored obesity coverage options to expand access to patientsZepbound® (tirzepatide) KwikPen® for single-patient use available from Lilly at $449 across all doses through the Lilly Employer Connect platform, with reduced cost-share pricing available to employeesFlexible benefit designs expand access to obesity treatment while aligning with employer needs and budgetsINDIANAPOLIS, March 5, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced the launch of its Employer Connect platform, introducing new options to help close the access gap in U.S. obesity care. Lilly's platform expands choice, empowering employers to coordinate with independent program administrators to develop flexible, transparent solutions that enable employee access